Lataa...
711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)
BACKGROUND: Exebacase (CF-301) is a novel, recombinantly-produced, bacteriophage-derived lysin (cell wall hydrolase) which is the first lysin to report Phase 2 (Ph2) results which demonstrated 42.8% higher clinical responder rates with a single dose of exebacase used in addition to standard of care...
Tallennettuna:
| Julkaisussa: | Open Forum Infect Dis |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6811034/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.779 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|